PTC Therapeutics Q1 product revenue rises 47%, raises FY guidance
PTC Therapeutics, Inc. PTCT | 0.00 |
Overview
US biopharma firm's Q1 2026 product revenue rose 47% yr/yr, driven by Sephience launch
Company raised full-year 2026 product revenue guidance to $750-$850 mln
PTC reported a Q1 net loss of $2.8 mln, compared to net income last year
Outlook
PTC raises 2026 total product revenue guidance to $750 mln-$850 mln
Company expects 2026 total revenue of $1.08 bln-$1.18 bln
PTC maintains 2026 GAAP and non-GAAP R&D and SG&A expense guidance
Result Drivers
SEPHIENCE LAUNCH MOMENTUM - Strong global launch of Sephience drove 36% qtr/qtr revenue growth, with expanding sales in the US and internationally
ROYALTY REVENUE INCREASE - Higher royalties from Evrysdi contributed to revenue growth
GENERIC EROSION - Emflaza revenue declined due to continued generic competition
Company press release: ID:nPn2DnB9Qa
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q1 Product Revenue |
|
$225.57 mln |
|
Q1 EPS |
|
-$0.03 |
|
Q1 Net Income |
|
-$2.81 mln |
|
Q1 Basic EPS |
|
-$0.03 |
|
Q1 Operating Expenses |
|
$227.59 mln |
|
Q1 Operating Income |
|
$44.96 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for PTC Therapeutics Inc is $83.50, about 25.4% above its May 6 closing price of $66.57
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.